Pradaxa Related Published Studies
Well-designed clinical trials related to Pradaxa (Dabigatran)
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients
With Atrial Fibrillation (RELY-ABLE) Study. [2013]
Dabigatran vs. placebo in patients with acute coronary syndromes on dual
antiplatelet therapy: a randomized, double-blind, phase II trial. [2011]
Dabigatran compared with warfarin in patients with atrial fibrillation and
previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY
trial. [2010]
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip
or knee arthroplasty: a pooled analysis of three trials. [2010]
Insights from the dabigatran versus warfarin trial in patients with venous
thromboembolism (the RE-COVER trial). [2010]
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant
therapy, warfarin, compared with dabigatran. [2009]
Nelarabine. [2008]
Well-designed clinical trials possibly related to Pradaxa (Dabigatran)
Aspirin for prevention and treatment of venous thromboembolism. [2014]
New oral anticoagulants and the risk of intracranial hemorrhage: traditional and
Bayesian meta-analysis and mixed treatment comparison of randomized trials of new
oral anticoagulants in atrial fibrillation. [2013]
Thromboprophylaxis in patients older than 75 years or with moderate renal
impairment undergoing knee or hip replacement surgery [corrected]. [2012]
Anticoagulating obese patients in the modern era. [2011]
Other research related to Pradaxa (Dabigatran)
Evaluation of dabigatran utilization and risk among hospitalized patients. [2014]
Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine
clinical practice. [2014]
Major bleeding with dabigatran and rivaroxaban in patients with atrial
fibrillation: a real-world setting. [2014]
Warfarin or dabigatran for treatment of atrial fibrillation. [2014]
Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial
fibrillation: the RE-LY study and substudies with commentary. [2013]
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin
in atrial fibrillation. [2013]
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and
bleeding in Asians and non-Asians with atrial fibrillation. [2013]
Dabigatran: is there a role for coagulation assays in guiding therapy? [2013]
Dabigatran for the prevention of stroke and systemic embolism in atrial
fibrillation: A NICE single technology appraisal. [2013]
Dabigatran does not prolong the QT interval with supratherapeutic exposure: a
thorough QT study in healthy subjects. [2013]
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the
Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. [2013]
A randomised study of dabigatran in elective percutaneous coronary intervention
in stable coronary artery disease patients. [2013]
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran
etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. [2011]
Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. [2011]
Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. [2011]
Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily
clinical practice. [2010]
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery:
exploratory indirect comparison based on meta-analysis of pivotal clinical
trials. [2010]
Insights from the dabigatran versus warfarin in patients with atrial fibrillation
(RE-LY) trial. [2010]
Dabigatran etexilate prevents venous thromboembolism after total knee
arthroplasty in Japanese patients with a safety profile comparable to placebo. [2010]
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. [2009]
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen
for prevention of venous thromboembolism after knee arthroplasty surgery. [2009]
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. [2008]
Dabigatran with or without concomitant aspirin compared with warfarin alone in
patients with nonvalvular atrial fibrillation (PETRO Study). [2007]
Other possibly related research studies
Update on the management of atrial fibrillation: anticoagulation and medical
therapy. [2011]
The new oral anticoagulants, do they change the benefit vs. risk for
thromboprophylaxis in association to ambulatory surgery? [2010]
Does warfarin for stroke thromboprophylaxis protect against MI in atrial
fibrillation patients? [2010]
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight
heparins for prevention of venous thromboembolism following total hip or knee
replacement. [2010]
Antithrombotic treatment failures in antiphospholipid syndrome: the new
anticoagulants? [2010]
Prevention and treatment of thromboembolic events in medical patients and new
anticoagulants. [2009]
New oral anticoagulants: not quite there yet. [2009]
Efficacy and safety of novel oral anticoagulants for treatment of acute venous
thromboembolism: direct and adjusted indirect meta-analysis of randomised
controlled trials. [2012]
Emerging oral anticoagulants for stroke prevention in patients with non-valvular
atrial fibrillation. [2012]
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in
patients with atrial fibrillation. [2013]
New oral anticoagulants in elderly patients. [2013]
Use of new oral anticoagulants in antiphospholipid syndrome. [2013]
Implications of new anticoagulants in primary practice. [2013]
Novel oral anticoagulants in acute coronary syndrome. [2013]
Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants. [2013]
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis
of randomized trials. [2014]
Treatment discontinuations with new oral agents for long-term anticoagulation:
insights from a meta-analysis of 18 randomized trials including 101,801 patients. [2014]
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? [2014]
Comparisons between novel oral anticoagulants and vitamin K antagonists in
patients with CKD. [2014]
Development of a tool to identify patients' preference for vitamin K antagonist
or direct oral anticoagulant therapy. [2014]
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K
antagonists in the treatment of acute symptomatic venous thromboembolism: a
systematic review and meta-analysis. [2014]
New oral anticoagulants and the cancer patient. [2014]
New oral anticoagulants are not superior to warfarin in secondary prevention of
stroke or transient ischemic attacks, but lower the risk of intracranial
bleeding: insights from a meta-analysis and indirect treatment comparisons. [2013]
Meta-analysis of randomized controlled trials on risk of myocardial infarction
from the use of oral direct thrombin inhibitors. [2013]
Eligibility and preference of new oral anticoagulants in patients with atrial
fibrillation: comparison between patients with versus without stroke. [2014]
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? [2014]
Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer
oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation
and proposal of a management algorithm. [2014]
A new class of powerful and informative simultaneous confidence intervals. [2014]
Beyond warfarin: a patient-centered approach to selecting novel oral
anticoagulants for stroke prevention in atrial fibrillation. [2014]
|
